Home / Biotechnology / Hospital Acquired Disease Testing Market by Infection Type (Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, MRSA) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Hospital Acquired Disease Testing Market by Infection Type (Pneumonia, Urinary Tract Infection, Blood Stream Infection, Surgical Site Infection, MRSA) - Growth, Share, Opportunities & Competitive Analysis, 2015 - 2022

Published: May 2016 | Report Code: 57814-05-16

Hospital acquired infections (HAI) or diseases, also called as nosocomial infections are acquired in healthcare in-patient settings. It is estimated that in the U.S., 9.2 out of every 100 parents acquire hospital infection. Urinary tract infection and pneumonia are the most common types of HAI, followed by bloodstream infection, and surgical site infection. These infections are caused by pathogens, among patients with compromised immunity. Patients may also develop HAIs due to sub-standard healthcare settings and negligence on the part of hospital staff. The mortality and morbidity of HAIs and the associated costs has urged caregivers for devising efficient infection control strategies. Accurate and in-time diagnosis of HAIs are vital for efficient control and management of HAI.

The global hospital acquired disease testing market report studies this market in terms of major types of HAIs. These include hospital acquired pneumonia, urinary tract infection, bloodstream infection, surgical site infection, Methicillin-resistant Staphylococcus aureus (MRSA) and others. This report studies these segments in terms of their historical and future market size and forecast for the period 2014-2022. Respective compounded annual growth rates (CAGR %) for these segments for the period 2016-2022 are also presented in this study.

Geographically, the global hospital acquired disease testing market is studied for the following regional markets:

North America

a)       U.S.

b)       Canada

Europe

c)       U.K.

d)       Germany

e)       Rest of Europe

Asia-Pacific

f)        Japan

g)       China

h)       Rest of Asia-Pacific

Middle East and Africa

Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 are also provided in this report.

Qualitative information such as drivers, challenges and future prospects for the global hospital acquired disease testing market are included in this report. Competition assessment tools such as fractal map analysis and attractive investment proposition are presented in this study for scrutinizing competition of the global hospital acquired disease testing market. This study concludes with company profiles section that highlights information about the key companies engaged in development, manufacture and provision of hospital acquired disease testing products.

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Hospital Acquired Disease Testing Market, by Infection Type, 2015 (USD Mn)
2.2 Hospital Acquired Disease Testing Market Share, by Geography, 2015 (Value %)

Chapter 3 Hospital Acquired Disease Testing Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Drivers
3.3 Challenges
3.4 Future Prospects
3.5 Attractive Investment Proposition
3.1 Competitive Analysis: Fractal Map Investigation, by Key Market Players

Chapter 4 Global Hospital Acquired Disease Testing Market Analysis, by Infection Type
4.1 Preface
4.2 Pneumonia
4.3 Urinary Tract Infection
4.4 Blood Stream Infection
4.5 Surgical Site Infection
4.6 MRSA
4.7 Others

Chapter 5 Global Hospital Acquired Disease Testing Market, by Geography
5.1 Preface
5.2 North America
5.3 Europe
5.4 Asia-Pacific
5.5 Middle East and Africa (MEA)
5.6 Latin America

Chapter 6 Company Profiles
6.1 Becton Dickinson
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Positions/Portfolio
6.1.4 News Coverage
6.2 bioMerieux
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Positions/Portfolio
6.2.4 News Coverage
6.3 Cantel
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Positions/Portfolio
6.3.4 News Coverage
6.4 Cepheid
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Positions/Portfolio
6.4.4 News Coverage
6.5 Diatherix
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Positions/Portfolio
6.5.4 News Coverage
6.6 Qiagen
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product Positions/Portfolio
6.6.4 News Coverage
6.7 Nordion
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Positions/Portfolio
6.7.4 News Coverage
6.8 Roche
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Positions/Portfolio
6.8.4 News Coverage
6.9 Others
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Positions/Portfolio
6.9.4 News Coverage

List of Figures

FIG. 1 Hospital Acquired Disease Testing: Market Segmentation
FIG. 2 Hospital Acquired Disease Testing Market, by Infection Type, 2015 (USD Mn)
FIG. 3 Hospital Acquired Disease Testing Market Share, by Geography, 2015 (Value %)
FIG. 4 Attractive Investment Proposition, Hospital Acquired Disease Testing Market, 2015
FIG. 5 Competitive Analysis: Fractal Map Investigation, by Key Market Players
FIG. 6 Global Hospital Acquired Pneumonia Testing Market, 2014 – 2022 (USD Mn)
FIG. 7 Global Hospital Acquired Urinary Tract Infection Testing Market, 2014 – 2022 (USD Mn)
FIG. 8 Global Hospital Acquired Blood Stream Infection Testing Market, 2014 – 2022 (USD Mn)
FIG. 9 Global Hospital Acquired Surgical Site Infection Market, 2014 – 2022 (USD Mn)
FIG. 10 Global MRSA Testing Market, 2014 – 2022 (USD Mn)
FIG. 11 Global Other Hospital Acquired Diseases Testing Market, 2014 – 2022 (USD Mn)
FIG. 12 U.S. Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 13 Canada Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 14 U.K. Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 15 Germany Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 16 Rest of Europe Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 17 Japan Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 18 China Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 19 Rest of Asia-Pacific Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 20 Middle East and Africa Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)
FIG. 21 Latin America Hospital Acquired Disease Testing Market, 2014 - 2022 (USD Mn)

List of Tables

TABLE 1 Global Hospital Acquired Disease Testing Market, by Infection Type, 2014 – 2022 (USD Mn)
TABLE 2 Global Hospital Acquired Disease Testing Market, by Geography, 2014 – 2022 (USD Mn)
TABLE 3 North America Hospital Acquired Disease Testing Market, by Country, 2014 – 2022 (USD Mn)
TABLE 4 Europe Hospital Acquired Disease Testing Market, by Country, 2014 – 2022 (USD Mn)
TABLE 5 Asia-Pacific Hospital Acquired Disease Testing Market, by Country, 2014 – 2022 (USD Mn)

Infection Type Segmentation Investigation

Based on infection types, global hospital acquired disease testing market categorized into:

1.   Pneumonia

2.   Urinary tract infection

3.   Blood stream infection

4.   Surgical site infection

5.   MRSA

6.   Others

Hospital Acquired Disease Testing Market

Pneumonia and urinary tract infection are the most common hospital acquired infections and the largest market segments in 2015. Nosocomial pneumonia, healthcare associated pneumonia and ventilator-associated pneumonia are the chief causes of mortality and morbidity in hospital settings. Surgical site infection is the third common nosocomial infection and involves skin, muscle and subcutaneous tissue. The attributable mortality of blood stream infection is 20%, thus making this segment among the deadliest conditions and thus the most addresseable.

Based on geographical segmentation, the global hospital acquired disease testing market is studied for:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Hospital Acquired Disease Testing Market

The regional classification is further elucidated as follows:

  • North America (U.S. & Canada)
  • Europe (U.K., Germany and Rest of Europe)
  • Asia-Pacific (Japan, China and Rest of Asia-Pacific)
  • Middle East and Africa
  • Latin America

North America is the largest market for hospital acquired disease testing, due to multitude of hospital admissions, and the growing need for containment of rising morbidity. Stringent guidelines for infection reduction and thus culminating the risk of readmission in hospitals have urged the emerging markets to grow at a rapid CAGR during the forecast period.

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients